Total Payments
$1.2M
2024 Payments
$120,576
Companies
60
Transactions
1,987
Medicare Patients
2,362
Medicare Billing
$295,772
Payment Breakdown by Category
Other$868,283 (72.9%)
Consulting$166,841 (14.0%)
Travel$88,277 (7.4%)
Food & Beverage$60,927 (5.1%)
Gifts$2,733 (0.2%)
Research$2,485 (0.2%)
Education$724.64 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $836,048 | 310 | 70.2% |
| Consulting Fee | $166,841 | 58 | 14.0% |
| Travel and Lodging | $88,277 | 498 | 7.4% |
| Food and Beverage | $60,927 | 1,079 | 5.1% |
| Honoraria | $32,235 | 11 | 2.7% |
| Gift | $2,733 | 2 | 0.2% |
| Unspecified | $2,485 | 16 | 0.2% |
| Education | $724.64 | 13 | 0.1% |
Payments by Type
General
$1.2M
1,971 transactions
Research
$2,485
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $425,242 | 542 | $0 (2024) |
| Biogen, Inc. | $196,732 | 258 | $0 (2024) |
| EMD Serono, Inc. | $172,069 | 268 | $0 (2024) |
| Genentech USA, Inc. | $72,504 | 126 | $0 (2024) |
| Horizon Therapeutics plc | $66,495 | 83 | $0 (2023) |
| Lilly USA, LLC | $46,234 | 90 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $39,244 | 82 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $29,538 | 21 | $0 (2024) |
| Celgene Corporation | $28,161 | 70 | $0 (2024) |
| Amgen Inc. | $25,666 | 53 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $120,576 | 200 | Lilly USA, LLC ($34,930) |
| 2023 | $141,505 | 232 | EMD Serono, Inc. ($37,483) |
| 2022 | $152,691 | 239 | Horizon Therapeutics plc ($35,378) |
| 2021 | $97,373 | 150 | Biogen, Inc. ($40,063) |
| 2020 | $94,636 | 168 | EMD Serono, Inc. ($27,877) |
| 2019 | $201,822 | 356 | GENZYME CORPORATION ($76,440) |
| 2018 | $162,190 | 282 | GENZYME CORPORATION ($87,917) |
| 2017 | $219,479 | 360 | GENZYME CORPORATION ($188,996) |
All Payment Transactions
1,987 individual payment records from CMS Open Payments — Page 1 of 80
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $139.02 | General |
| 12/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $45.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $33.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $29.48 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $87.23 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $29.25 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/06/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $42.25 | General |
| Category: PAIN | ||||||
| 12/06/2024 | Lilly USA, LLC | KISUNLA (Drug) | Travel and Lodging | Cash or cash equivalent | $37.05 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | Lilly USA, LLC | KISUNLA (Drug) | Travel and Lodging | Cash or cash equivalent | $19.23 | General |
| Category: Neuroscience | ||||||
| 12/02/2024 | Lilly USA, LLC | KISUNLA (Drug) | Travel and Lodging | Cash or cash equivalent | $66.00 | General |
| Category: Neuroscience | ||||||
| 12/02/2024 | Lilly USA, LLC | KISUNLA (Drug) | Travel and Lodging | Cash or cash equivalent | $30.02 | General |
| Category: Neuroscience | ||||||
| 11/26/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Neuroscience | ||||||
| 11/26/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Neuroscience | ||||||
| 11/26/2024 | Baxter Healthcare | Hillrom - Vest System Model 105 Home Care (Device) | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: Airway Clearance Device | ||||||
| 11/25/2024 | Lilly USA, LLC | KISUNLA (Drug) | Consulting Fee | Cash or cash equivalent | $5,775.00 | General |
| Category: Neuroscience | ||||||
| 11/25/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Neuroscience | ||||||
| 11/25/2024 | Lilly USA, LLC | KISUNLA (Drug) | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| Category: Neuroscience | ||||||
| 11/25/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $69.62 | General |
| 11/22/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $78.97 | General |
| 11/21/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | Cash or cash equivalent | $118.03 | General |
| Category: Neuroscience | ||||||
| 11/21/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $25.46 | General |
| Category: Neuroscience | ||||||
| 11/20/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,850.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | SANOFI US SERVICES INC. | $2,485 | 16 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 519 | 752 | $140,150 | $64,809 |
| 2022 | 6 | 550 | 770 | $145,815 | $71,409 |
| 2021 | 6 | 663 | 969 | $184,559 | $89,963 |
| 2020 | 7 | 630 | 912 | $162,542 | $69,591 |
Total Patients
2,362
Total Services
3,403
Medicare Billing
$295,772
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 194 | 334 | $34,803 | $21,071 | 60.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 142 | 196 | $32,036 | $15,752 | 49.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 86 | 86 | $29,412 | $13,517 | 46.0% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 32 | 63 | $22,050 | $4,737 | 21.5% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 29 | 29 | $12,760 | $4,737 | 37.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 31 | $7,347 | $4,019 | 54.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 11 | 13 | $1,742 | $977.21 | 56.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 200 | 321 | $33,451 | $21,397 | 64.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 143 | 202 | $32,926 | $17,439 | 53.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 104 | 104 | $35,568 | $16,732 | 47.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 42 | 52 | $12,425 | $6,765 | 54.4% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 26 | 51 | $17,850 | $4,007 | 22.4% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 24 | 25 | $11,000 | $3,924 | 35.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 11 | 15 | $2,595 | $1,145 | 44.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 238 | 419 | $43,710 | $26,974 | 61.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 156 | 222 | $36,274 | $19,912 | 54.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 122 | 122 | $41,724 | $19,874 | 47.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 52 | 63 | $15,032 | $8,397 | 55.9% |
| 95911 | Nerve transmission studies, 9-10 studies | Office | 2021 | 35 | 37 | $16,280 | $6,609 | 40.6% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 37 | 77 | $26,950 | $6,195 | 23.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 12 | 16 | $3,653 | $1,474 | 40.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 11 | 13 | $936.00 | $528.48 | 56.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 293 | 503 | $52,379 | $26,165 | 50.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 93 | 93 | $31,806 | $13,880 | 43.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 122 | 158 | $25,754 | $12,066 | 46.8% |
About Dr. Nida Laurin, M.D
Dr. Nida Laurin, M.D is a Neurology healthcare provider based in Scottsdale, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306887963.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nida Laurin, M.D has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $120,576 received in 2024. These payments were reported across 1,987 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($836,048).
As a Medicare-enrolled provider, Laurin has provided services to 2,362 Medicare beneficiaries, totaling 3,403 services with total Medicare billing of $295,772. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Scottsdale, AZ
- Active Since 06/08/2006
- Last Updated 08/12/2011
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1306887963
Products in Payments
- AUBAGIO (Drug) $184,769
- LEMTRADA (Drug) $182,511
- Mavenclad (Drug) $77,350
- TYSABRI (Biological) $74,309
- UPLIZNA (Drug) $66,495
- OCREVUS (Biological) $54,026
- ZEPOSIA (Drug) $47,315
- VUMERITY (Drug) $40,891
- KISUNLA (Drug) $33,747
- MAVENCLAD (Drug) $27,866
- Mavenclad (Biological) $27,431
- TECFIDERA (Drug) $18,724
- UPLIZNA (Biological) $18,534
- UBRELVY (Drug) $16,724
- Rebif (Biological) $15,929
- BAFIERTAM (Drug) $14,896
- Non-Covered Product (Drug) $12,857
- Tysabri (Biological) $11,329
- DISEASE STATE (Drug) $11,158
- Evobrutinib $7,200
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Scottsdale
Dr. Amaal Starling, M.d, M.D
Neurology — Payments: $314,467
Neurology $314,467
Dr. Dean Wingerchuk, M.d, M.D
Neurology — Payments: $314,438
Neurology $314,438
Dr. Virgilio Evidente, M.d, M.D
Neurology — Payments: $280,162
Neurology $280,162
David Saperstein, Md, MD
Neurology — Payments: $173,854
Neurology $173,854
Dr. Cornelia Drees, M.d, M.D
Neurology — Payments: $171,652
Neurology $171,652
Dr. Charles Adler, M.d, M.D
Neurology — Payments: $112,803
Neurology $112,803